CRTX - Cortexyme, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
72.51
+8.41 (+13.12%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close64.10
Open66.35
Bid0.00 x 1400
Ask98.00 x 800
Day's Range63.61 - 73.84
52 Week Range19.35 - 73.84
Volume232,252
Avg. Volume213,788
Market Cap2.128B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.25
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est72.60
  • Business Wire

    Cortexyme Provides Regulatory Update for COR388 Development Program in Alzheimer’s Disease

    Cortexyme, Inc. (Nasdaq: CRTX) today provided an update on its clinical development plans for COR388, the company’s lead investigational medicine in development for mild to moderate Alzheimer’s disease (AD). The company conducted a Type C meeting with the FDA gathering agreement and feedback on development plans through NDA, including the Phase 2/3 GAIN Trial statistical analysis plan, metabolite characterization, nonclinical studies, population pharmacokinetics, and drug-drug interaction studies.

  • Business Wire

    Cortexyme Announces Closing of $125 Million Private Placement

    Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, today announced that it has closed its private placement offering. The Company issued 2,500,000 shares of common stock for a purchase price of $50.00 per share, resulting in gross proceeds to the Company of $125 million, before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from the private placement primarily to advance clinical development, as well as for general corporate purposes.

  • Business Wire

    Cortexyme Announces $125 Million Private Placement

    Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, today announced that it has entered into stock purchase agreements with a group of institutional investors and an entity affiliated with a member of the Company’s Board of Directors in connection with a private placement of its common stock. The transaction is expected to result in gross proceeds to the Company of $125 million, before deducting placement agent fees and other offering expenses. The Company plans to use the net proceeds from the private placement primarily to advance clinical development, as well as for general corporate purposes.

  • Business Wire

    Cortexyme Announces Publication of New Data Further Demonstrating the Therapeutic Potential of COR388, the Company’s Lead Investigational Medicine

    Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, today announced the publication of new data in Pharmacology Research and Perspectives revealing further detail about the pharmacodynamics and utility of the company’s lead investigational medicine, COR388. The data provides additional evidence on the ability of COR388 to engage its target, the toxic proteases, or gingipains, released by the bacterium P. gingivalis and the closely related species P. gulae, resulting in beneficial effects on bacterial load and symptoms.

  • Business Wire

    Cortexyme Announces the Initiation of an Open-Label Extension Study for the GAIN Trial of COR388 in Alzheimer’s Disease

    Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced it is initiating an open-label extension study in the United States for its Phase 2/3 GAIN Trial of COR388 in subjects with mild to moderate Alzheimer’s disease (AD). Additionally, the GAIN Trial Data Monitoring Committee recently completed its first planned safety review and recommended continuation of the study as planned.

  • Business Wire

    Cortexyme to Present at the 3rd Annual Neuroscience Innovation Forum on January 12, 2020

    Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder will present at the 3rd Annual Neuroscience Innovation Forum on Sunday, January 12, 2020 at 3:45 p.m. PST / 6:45 p.m. EST. The Forum will take place on the eve of the J.P. Morgan Healthcare Conference in downtown San Francisco.

  • Here's Why We're Not Too Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Situation
    Simply Wall St.

    Here's Why We're Not Too Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Situation

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • American City Business Journals

    Last year's Bay Area IPO performances show why it pays to be an insider

    Timing is everything: Here's a look at the big gap in returns for public and private investors in the best performing new Bay Area stocks from last year.

  • Hedge Funds Have Never Been This Bullish On Cortexyme, Inc. (CRTX)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Cortexyme, Inc. (CRTX)

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

  • The Zacks Analyst Blog Highlights: Alibaba, Beyond Meat, Cortexyme, Revolve and Uber
    Zacks

    The Zacks Analyst Blog Highlights: Alibaba, Beyond Meat, Cortexyme, Revolve and Uber

    The Zacks Analyst Blog Highlights: Alibaba, Beyond Meat, Cortexyme, Revolve and Uber

  • 5 Hottest IPOs of 2019
    Zacks

    5 Hottest IPOs of 2019

    2019 was one of the busiest years for IPOs, and the calendar was packed with big tech unicorns and popular consumer brands. Here are some of the hottest market debuts we saw this year.

  • Fiverr Languishes Below IPO Price as First Chance to Sell Nears
    Bloomberg

    Fiverr Languishes Below IPO Price as First Chance to Sell Nears

    (Bloomberg) -- Fiverr International Ltd.’s initial zing has almost entirely faded since its June IPO, with the stock falling for six straight days to below its IPO price as insiders’ and early investors’ first chance to sell looms on Tuesday.The biggest stakeholders include Viola Private Equity’s Jonathan Kolber, Deer VII & Co., Accel London III Associates, Square Peg Group, and co-founder and chief executive officer Micha Kaufman, according to data compiled by Bloomberg. But post-IPO stock weakness, with shares off the June high of $44 by more than 52%, make it less likely shareholders will walk away.Fiverr chief Kaufman was unavailable to respond to queries.The operator of an online marketplace for software services had the fourth-best debut of this year’s 239 IPOs, rising a whopping 90% from offer to its first close. That ranks just behind Beyond Meat Inc., Adaptive Biotechnologies Corp., and Cortexyme Inc., each of which has done better hanging on to initial gains. Underwriters on the Fiverr IPO were JPMorgan, Citi, BofA, UBS, Oppenheimer, Needham, and JMP Securities.Analysts appear split, with four buy, three hold and no sell ratings on the stock, according to data compiled by Bloomberg. But with price targets ranging from $22 to $34, they seem to agree that debut highs are unlikely to be seen again anytime soon. To contact the reporter on this story: Crystal Kim in New York at ckim426@bloomberg.netTo contact the editors responsible for this story: Brad Olesen at bolesen3@bloomberg.net, Scott SchnipperFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • MarketWatch

    Biogen's shares drop on critical view of Alzheimer's data

    Biogen shares fell 2.6% after an analyst scoffed at the possibility of a Food and Drug Administration approval for the company's experimental Alzheimer's disease treatment. "There are so many reasons we think aducanumab is getting rejected, our word count restrictions don't allow us to put them all here," Baird analyst Brian Skorney wrote in a Dec. 2 note. Skorney's primary argument is that he believes data from the most recent clinical trial doesn't make for a compelling case to take to the FDA. Earlier this year, Biogen's stock tumbled to a three-year low after the company said it would stop trials for the therapy, prompting Mizuho analyst Salim Syed to say "aducanumab is dead, and we'd argue so is the beta-amyloid hypothesis." But then in October Biogen announced plans to pursue FDA approval following discussions with the regulator. The biopharmaceutical company has said it will release additional clinical trial information about aducanumab on Dec. 5. Separately, shares of Cortexyme Inc. , which is also developing an Alzheimer's treatment, jumped in morning trading, by 20%. Shares of Biogen have fallen about 3% year-to-date, compared to the S&P 500 , which has gained about 24%.

  • The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme
    Zacks

    The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme

    The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme

  • 4 Best-Performing IPOs So Far in 2019
    Zacks

    4 Best-Performing IPOs So Far in 2019

    Companies that went public this year and did well in terms of price performance did so on the back of solid financials, positive cash flows and growing revenues.

  • Top Ranked Momentum Stocks to Buy for October 9th
    Zacks

    Top Ranked Momentum Stocks to Buy for October 9th

    Top Ranked Momentum Stocks to Buy for October 9th

  • Did Cortexyme, Inc. (NASDAQ:CRTX) Insiders Buy Up More Shares?
    Simply Wall St.

    Did Cortexyme, Inc. (NASDAQ:CRTX) Insiders Buy Up More Shares?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • Top Ranked Momentum Stocks to Buy for September 23rd
    Zacks

    Top Ranked Momentum Stocks to Buy for September 23rd

    Top Ranked Momentum Stocks to Buy for September 23rd

  • What Percentage Of Cortexyme, Inc. (NASDAQ:CRTX) Shares Do Insiders Own?
    Simply Wall St.

    What Percentage Of Cortexyme, Inc. (NASDAQ:CRTX) Shares Do Insiders Own?

    The big shareholder groups in Cortexyme, Inc. (NASDAQ:CRTX) have power over the company. Generally speaking, as a...